---
title: "BofAS Raises CSPC PHARMA  TP to HKD8.6, Reiterates Underperform Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296562815.md"
description: "BofAS raised CSPC PHARMA's target price to HKD8.6 from HKD7.6 and increased net profit forecasts for 2026-2028, citing strong H1 revenue and profit growth. However, the bank reiterated its 'Underperform' rating due to pricing pressure on key drug NBP."
datetime: "2026-08-21T03:21:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296562815.md)
  - [en](https://longbridge.com/en/news/296562815.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296562815.md)
generator: "portal-rs"
---

# BofAS Raises CSPC PHARMA  TP to HKD8.6, Reiterates Underperform Rating

BofAS issued a report saying that CSPC PHARMA (01093.HK) -0.350 (-3.676%) Short selling $478.25M; Ratio 11.096% 's total revenue/ net profit attributable for 1H26 rose 40.1%/ 139.2% YoY to RMB18.6 billion/ RMB6.1 billion respectively. In 2Q alone, total revenue increased 93.8% YoY to RMB12.1 billion. Net profit attributable surged 389.3% YoY to RMB5.2 billion.

The broker raised its 2026-2028 net profit forecasts for CSPC PHARMA (01093.HK) -0.350 (-3.676%) Short selling $478.25M; Ratio 11.096% by 1.9%, 2.6% and 1.6% respectively, and lifted its TP from HKD7.6 to HKD8.6. However, it reiterated the "Underperform" rating due to pricing pressure faced by its key drug NBP.

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [CSPC wins China clinical trial approval for SYH2083 dry eye drops](https://longbridge.com/en/news/298295585.md)
- [CSPC Pharma wins China NMPA clearance to start Phase 1 trial of SYH2092 obesity drug](https://longbridge.com/en/news/297512143.md)
- [Promise Launches Clinician-Guided BPC-157 Evaluation as FDA Panel Backs 503A Bulks List Addition](https://longbridge.com/en/news/298349678.md)
- [DisposeRx Launches The Medication Stewardship Center to help redefine how each of us thinks about our own and our families' prescription journeys](https://longbridge.com/en/news/298490700.md)
- [U.S. Department of Health names heads of FDA drug, biologics centers](https://longbridge.com/en/news/298364797.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**